Clinical Trials Logo

Filter by:
NCT ID: NCT06109064 Recruiting - Clinical trials for Myelodysplastic Syndromes

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.

NCT ID: NCT06108830 Recruiting - Sleep Disturbance Clinical Trials

Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies

NCT ID: NCT06108739 Recruiting - Clinical trials for Hematologic Malignancy

ATG Plus Low-dose PT-Cy for GVHD Prevention

Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

During the past decades, the wider application of easily available haploidentical donor hematopoietic cell transplant (haplo-HCT) has been made possible through the T cell-replete (TCR) regimens including T cell regulation with anti-thymocyte globulin (ATG)/granulocyte colony-stimulating factor (GCSF) and post-transplant cyclophosphamide (PTCy). To achieve decreased non-relapse mortality (NRM) and improved long-term outcomes in haploidentical transplant, the joint use of ATG and PTCy might effectively reduce graft versus host disease (GVHD) and mortality associated with severe forms of GVHD. Recently, investigators established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse.

NCT ID: NCT06108726 Recruiting - NSCLC Clinical Trials

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

Start date: October 18, 2023
Phase: Phase 2
Study type: Interventional

The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy of local injection of envafolimab combined with chemotherapy in the first-line treatment of non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in the local immune microenvironment before and after immunotherapy, in order to find new indicators for immunotherapy evaluation.

NCT ID: NCT06108596 Recruiting - Clinical trials for Locally Advanced Rectal Adenocarcinoma

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Start date: December 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for locally advanced rectal cancer - a single-center, single-arm, open-label clinical trail.

NCT ID: NCT06108531 Enrolling by invitation - Pancreatic Clinical Trials

Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

Start date: November 1, 2023
Phase:
Study type: Observational

This is an observational study of patients diagnosed with pancreatic cancer by pathology, with a control group of patients with pathology suggestive of benign pancreatic lesions and normal subjects, and the diagnostic ability of exosomes to identify patients with pancreatic cancer was assessed through the detection of exosomes in the peripheral blood.

NCT ID: NCT06108492 Recruiting - Clinical trials for High-risk Non-muscle Invasive Bladder Cancer

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with high-risk non-muscle invasive bladder cancer.

NCT ID: NCT06108362 Recruiting - Acute Kidney Injury Clinical Trials

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

Start date: August 18, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

NCT ID: NCT06107790 Completed - Clinical trials for HER2-positive Breast Cancer

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Start date: May 16, 2018
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety and Immunogenicity of Vinorelbine Bitartrate Injection in Combination With HS022 and Trastuzumab®.There were 2 parts. Part 1 needs 8 treatment cycles ( at least 24 weeks); Part2 needs 9 treatment cycles (at least 27 weeks).

NCT ID: NCT06107686 Active, not recruiting - Breast Cancer Clinical Trials

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Start date: December 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.